Factor 5 Leiden Mutation: Causes, Symptoms & Treatment
The Factor 5 Leiden mutation is a genetic change that significantly increases the risk of blood clots. It is the most common inherited cause of clotting disorders in people of European descent.
Things worth knowing about "Factor 5 Leiden Mutation"
The Factor 5 Leiden mutation is a genetic change that significantly increases the risk of blood clots. It is the most common inherited cause of clotting disorders in people of European descent.
What Is the Factor 5 Leiden Mutation?
The Factor 5 Leiden mutation (also written as Factor V Leiden mutation) is a genetic variant in the gene encoding clotting factor V. This variant prevents factor V from being properly inactivated, causing the blood to remain in an overactive clotting state. As a result, affected individuals have a significantly increased risk of developing blood clots (thrombosis). It is the most common inherited thrombophilia in European populations, affecting approximately 3–8% of individuals of European descent.
Causes and Inheritance
The mutation is caused by a single nucleotide substitution in the F5 gene on chromosome 1 (guanine replaced by adenine, G1691A). This leads to an amino acid change in the factor V protein (arginine replaced by glutamine at position 506, R506Q), making the mutated factor V resistant to inactivation by the natural anticoagulant activated protein C (APC).
The mutation follows an autosomal dominant inheritance pattern:
- Heterozygous carriers: One mutated copy – the risk of thrombosis is 3–8 times higher than average.
- Homozygous carriers: Two mutated copies – the risk of thrombosis is 50–80 times higher than average.
Symptoms and Clinical Presentation
The Factor 5 Leiden mutation itself does not cause direct symptoms. However, it significantly increases the risk of the following conditions:
- Deep vein thrombosis (DVT): Blood clots forming in the deep veins, most often in the legs
- Pulmonary embolism: A clot traveling to and blocking an artery in the lungs
- Pregnancy complications: Recurrent miscarriage, preeclampsia, placental insufficiency
- Stroke or heart attack (less common, usually in combination with additional risk factors)
Many carriers of the mutation never experience a thrombotic event, especially in the absence of additional risk factors.
Risk Factors
The thrombosis risk increases substantially when the Factor 5 Leiden mutation is combined with other risk factors such as:
- Use of estrogen-containing contraceptives (combined oral contraceptive pill)
- Pregnancy and the postpartum period
- Prolonged immobility (e.g., bed rest, long-haul flights)
- Surgery or injury
- Additional clotting disorders (e.g., prothrombin mutation, antiphospholipid syndrome)
- Obesity, smoking, or advanced age
Diagnosis
Diagnosis is established through laboratory testing on a blood sample, using two main approaches:
- APC resistance test (functional): Measures whether factor V responds normally to activated protein C. An abnormal result suggests the presence of the mutation.
- Genetic testing (DNA analysis): Confirms the presence of the mutation and determines whether the individual is a heterozygous or homozygous carrier.
Testing is typically recommended in individuals with:
- Unexplained or recurrent thrombosis, especially at a young age
- A family history of blood clotting disorders
- Thrombosis at unusual sites (e.g., mesenteric or cerebral veins)
- Recurrent pregnancy loss
Treatment and Management
Carriers of the Factor 5 Leiden mutation do not automatically require treatment. Management is individualized based on the overall thrombotic risk assessment.
Preventive Measures in High-Risk Situations
- Heparin injections during high-risk periods (surgery, pregnancy, prolonged immobility)
- Wearing compression stockings to improve venous blood flow
- Avoiding estrogen-containing contraceptives when the mutation is known
Treatment After a Thrombotic Event
- Anticoagulation therapy using direct oral anticoagulants (DOACs) such as rivaroxaban or apixaban, or vitamin K antagonists (e.g., warfarin)
- Duration of anticoagulation depends on individual risk (ranging from 3 months to lifelong therapy)
Pregnancy
Pregnant carriers are often treated with low-molecular-weight heparin, as DOACs are contraindicated during pregnancy. Treatment decisions are made on an individual basis in close consultation with a physician.
References
- Rosendaal FR - Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167–1173.
- Dahlbäck B - Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008;112(1):19–27.
- American Society of Hematology - Factor V Leiden Thrombophilia. ASH Clinical Practice Guidelines, 2023. Available at: www.hematology.org
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryPertussis vaccination
Urine color
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Factor 5 Leiden Mutation